This HTML5 document contains 133 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n11http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q33338982
rdf:type
wikibase:Item
schema:description
article científic article scientific artigo científico (publicado na 2001) ২০০১-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2001年论文 naučni članak vetenskaplig artikel vitenskapelig artikkel научни чланак מאמר מדעי مقالهٔ علمی wissenschaftlicher Artikel мақолаи илмӣ 2001年論文 2001年論文 2001年论文 artículu científicu espublizáu en 2001 научна статия 2001 թվականի հոտեմբերին հրատարակված գիտական հոդված articol științific мақолаи илмӣ artículo científico publicado en 2001 vitskapeleg artikkel 2001年论文 bài báo khoa học videnskabelig artikel (udgivet 2001) tudományos cikk artikulong pang-agham مقالة علمية tieteellinen artikkeli наукова стаття, опублікована в жовтні 2001 2001年論文 2001年論文 2001年论文 scienca artikolo 2001년 논문 სამეცნიერო სტატია vedecký článok 2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած article scientifique (publié 2001) vědecký článek επιστημονικό άρθρο teaduslik artikkel artikull shkencor научни чланак mokslinis straipsnis artykuł naukowy 2001年の論文 سائنسی مضمون 2001年论文 artigo científico (publicado na 2001) scientific article 2001年論文 научная статья bilimsel makale artigo científico 2001年论文 2001 nî lūn-bûn บทความทางวิทยาศาสตร์ articolo scientifico wetenschappelijk artikel
p:P577
wds:Q33338982-22E9DDD6-F0D3-4658-BF77-A2673016CB23
wdt:P577
2001-10-01T00:00:00Z
p:P2860
wds:Q33338982-16E87E7F-B8C0-4CA0-91D3-26D77E273CD9 wds:Q33338982-238BCA99-003E-491D-ADDD-5DDC07464E8C wds:Q33338982-12458F7F-3041-417A-9A62-33FFA947DDD2 wds:Q33338982-488D22F9-DBC4-46ED-A613-4BE1E5F2B6C8 wds:Q33338982-5D4801E4-BD0B-41A1-80AF-729B816FD414 wds:Q33338982-2A791A73-211A-4615-A82E-7C4600AB7D5C wds:Q33338982-3693357C-AE7E-4272-9ADE-8A2CA4DA39C3 wds:Q33338982-378D8133-1B6E-47C7-8DB8-466249978648 wds:Q33338982-65B4D0AE-0CB2-45EA-A71A-506020889956 wds:Q33338982-7901E60D-E83D-4C8B-9903-4EF4A123E039 wds:Q33338982-CBFA4F60-69CB-4AEE-B37B-CF7C58F94E24 wds:Q33338982-D2201EA3-64A2-421E-A9F6-BE7D37B99161 wds:Q33338982-E5FA127A-6AE5-4C46-9014-E9C666BAAF47
wdt:P2860
wd:Q33328193 wd:Q72426675 wd:Q73368715 wd:Q33489257 wd:Q33489695 wd:Q41388354 wd:Q33350574 wd:Q29620070 wd:Q45186433 wd:Q77613965 wd:Q45156394 wd:Q36771904 wd:Q33332853
p:P2093
wds:Q33338982-B7C42067-5BE2-4439-ADAE-8A3D7A1061A9 wds:Q33338982-C18AA45C-6C33-4A03-B4B7-AC32F7212E26 wds:Q33338982-A8F10DEA-6BE5-4776-8232-434DEAC918B4 wds:Q33338982-12C1F05B-378D-4826-AFFA-2D7C6FC12942 wds:Q33338982-314B4237-B586-4403-882D-68A5D90BFFF3 wds:Q33338982-4F99E48C-284F-40E1-A9F3-C32C6F1A7721 wds:Q33338982-A27E0781-8EFA-4D9A-8382-C42F1EB26EC7 wds:Q33338982-A5D9E670-67E8-426F-905D-B9FD91CE7C96
wdt:P2093
Mavroudis D Raptis A Kouroussis C Palamidas P Georgoulias V Agelaki S Kakolyris S Kalbakis K
rdfs:label
A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer
skos:prefLabel
A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer
schema:name
A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer
p:P1476
wds:Q33338982-9EDFB972-0DAC-4FEB-AA54-2864656BB6C9
wdt:P1476
A dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer
p:P304
wds:Q33338982-AE3B2A72-F9E4-4ABE-BBA7-D2E91F792965
wdt:P304
133-139
p:P31
wds:Q33338982-674C5D8C-D1B6-417D-8EB9-8B03B3EFF53F
wdt:P31
wd:Q13442814
p:P698
wds:Q33338982-98204A3B-FC94-4DF9-B93A-578DA19E8376
wdtn:P698
n9:11557123
wdt:P698
11557123
p:P1433
wds:Q33338982-271697A0-DF7A-435C-9358-22C0BF8F1A42
wdt:P1433
wd:Q641464
p:P433
wds:Q33338982-4308E1BA-E302-4CA4-A46E-928E266F4CB7
p:P478
wds:Q33338982-E9AF72CA-B3C9-4E86-9AC5-84A5908C6FDD
wdt:P433
1
wdt:P478
34
p:P356
wds:Q33338982-699E4F94-EF5D-4D3F-A61F-79506D5BE89C
wdtn:P356
n11:S0169-5002(01)00208-2
wdt:P356
10.1016/S0169-5002(01)00208-2